[1]刘燕燕,宋秀娟.卵圆孔未闭相关疾病的诊治进展[J].国际心血管病杂志,2022,05:282-284.
点击复制
卵圆孔未闭相关疾病的诊治进展(PDF)
《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]
- 期数:
- 2022年05期
- 页码:
- 282-284
- 栏目:
- 综述
- 出版日期:
- 2022-10-01
文章信息/Info
- Title:
- -
- Author(s):
- -
- Keywords:
- -
- 分类号:
- -
- DOI:
- 10.3969/j.issn.1673-6583.2022.05.008
- 文献标识码:
- -
- 摘要:
- 卵圆孔未闭是一种常见的先天性心脏病，且与多种疾病包括隐源性脑卒中、先 兆性偏头痛、减压病、低氧血症等相关。该文介绍卵圆孔未闭相关疾病的诊疗状况。
- Abstract:
- -
参考文献/References
[1] 张玉顺, 蒋世良, 朱鲜阳. 卵圆孔未闭相关卒中预防中国专
家指南[J]. 心脏杂志, 2021, 33(1):1-10.
[2] Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of
undetermined source: the case for a new clinical construct[J].
Lancet Neurol, 2014, 13(4):429-438.
[3] Yuan K, Kasner SE. Patent foramen ovale and cryptogenic
stroke: diagnosis and updates in secondary stroke
prevention[J]. Stroke Vasc Neurol, 2018, 3(2):84-91.
[4] Kent D, Ruthazer R, Weimar C, et al. An index to identify
stroke-related vs incidental patent foramen ovale in
cryptogenic stroke[J]. Neurology, 2013, 81(7):619-625.
[5] Mas JL, Derumeaux G, Guillon B, et al. Patent foramen ovale
closure or anticoagulation vs. antiplatelets after stroke[J]. N
Engl J Med, 2017, 377(11):1011-1021.
[6] S?ndergaard L, Kasner SE, Rhodes JF, et al. Patent foramen
ovale closure or antiplatelet therapy for cryptogenic stroke[J].
N Engl J Med, 2017, 377(11):1033-1042.
[7] Saver JL, Carroll JD, Thaler DE, et al. Long-term outcomes
of patent foramen ovale closure or medical therapy after
stroke[J]. N Engl J Med, 2017, 377(11):1022-1032.
[8] Lee PH, Song JK, Kim JS, et al. Cryptogenic stroke and highrisk
patent foramen ovale: the DEFENSE-PFO trial[J]. J Am
Coll Cardiol, 2018, 71(20):2335-2342.
[9] Vidale S, Russo F, Campana C, et al. Patent foramen ovale
closure versus medical therapy in cryptogenic strokes and
transient ischemic attacks: a meta-analysis of randomized
trials[J]. Angiology, 2019, 70(4):325-331.
[10] Romoli M, Giannandrea D, Eusebi P, et al. Aspirin or
anticoagulation after cryptogenic stroke with patent foramen
ovale: systematic review and meta-analysis of randomized
controlled trials[J]. Neurol Sci, 2020, 41(10):2819-2824.
[11] Angelini F, Fortuni F, Tsivgoulis G, et al. Comparison of
antithrombotic strategies in patients with cryptogenic stroke
and patent foramen ovale: an updated meta-analysis[J].
Cardiovasc Drugs Ther, 2021, 35(5):987-993.
[12] Kurth T, Rist PM, Ridker PM, et al. Association of migraine
with aura and other risk factors with incident cardiovascular
disease in women[J]. JAMA, 2020, 323(22):2281-2289.
[13] De Giuli V, Grassi M, Locatelli M, et al. Cardiac sources of
cerebral embolism in people with migraine[J]. Eur J Neurol,
2021, 28(2):516-524.
[14] Finocchi C, Del Sette M. Migraine with aura and patent
foramen ovale: myth or reality?[J]. Neurol Sci, 2015, 36(Suppl
1):61-66.
[15] Nozari A, Dilekoz E, Sukhotinsky I, et al. Microemboli may
link spreading depression, migraine aura, and patent foramen
ovale [J]. Ann Neurol, 2010, 67(2): 221-229.
[16] Caputi L, Usai S, Carriero MR, et al. Microembolic air load
during contrast-transcranial Doppler: a trigger for migraine
with aura?[J]. Headache, 2010, 50(8):1320-1327.
[17] Wilmshurst PT, Pearson MJ, Nightingale S, et al. Inheritance
of persistent foramen ovale and atrial septal defects and
the relation to familial migraine with aura[J]. Heart, 2004,
90(11):1315-1320.
[18] Dowson A, Mullen MJ, Peatfield R, et al. Migraine
Intervention With STARFlex Technology (MIST) trial: a
prospective, multicenter, double-blind, sham-controlled trial to
evaluate the effectiveness of patent foramen ovale closure with
STARFlex septal repair implant to resolve refractory migraine
headache[J]. Circulation, 2008, 117(11):1397-1404.
[19] Mattle HP, Evers S, Hildick-Smith D, et al. Percutaneous
closure of patent foramen ovale in migraine with aura, a
randomized controlled trial[J]. Eur Heart J, 2016, 37(26):2029-2036.
[20] Tobis JM, Charles A, Silberstein SD, et al. Percutaneous
closure of patent foramen ovale in patients with migraine: the
PREMIUM trial[J]. J Am Coll Cardiol, 2017, 70(22):2766-
2774.
[21] Mojadidi MK, Kumar P, Mahmoud AN, et al. Pooled analysis
of PFO occluder device trials in patients with PFO and
migraine[J]. J Am Coll Cardiol, 2021, 77(6):667-676.
[22] He Q, Zhang Y, Wang F, et al. Impact of right-to-left shunt and
transcatheter closure on the clinical features of migraine[J]. Int
J Neurosci, 2020, 130(3):270-275.
[23] Mas JL, Guillon B, Charles-Nelson A, et al. Patent foramen
ovale closure in stroke patients with migraine in the CLOSE
trial. The CLOSE-MIG study[J]. Eur J Neurol, 2021,
28(8):2700-2707.
[24] Sommer RJ, Nazif T, Privitera L, et al. Retrospective review
of thienopyridine therapy in migraineurs with patent foramen
ovale[J]. Neurology, 2018, 91(22):1002-1009.
[25] Honěk J, ?rámek M, ?efc L, et al. High-grade patent foramen
ovale is a risk factor of unprovoked decompression sickness in
recreational divers[J]. J Cardiol, 2019, 74(6):519-523.
[26] Honěk J, ?rámek M, Honěk T, et al. Patent poramen ovale
closure is effective in divers: long-term results from the DIVEPFO
registry[J]. J Am Coll Cardiol, 2020, 76(9):1149-1150.
[27] Anderson G, Ebersole D, Covington D, et al. The effectiveness
of risk mitigation interventions in divers with persistent
(patent) foramen ovale[J]. Diving Hyperb Med, 2019,
49(2):80-87.
[28] Vanden Eede M, Van Berendoncks A, De Wolfe D, et
al. Percutaneous closure of patent foramen ovale for the
secondary prevention of decompression illness in sports divers:
mind the gap[J]. Undersea Hyperb Med, 2019, 46(5):625-632.
[29] Allemann Y, Hutter D, Lipp E, et al. Patent foramen ovale
and high-altitude pulmonary edema[J]. JAMA, 2006,
296(24):2954-2958.
[30] 李肖楠, 刘春岭, 吴骏, 等. 阻塞性睡眠呼吸暂停低通气综合
征合并卵圆孔未闭的睡眠障碍特点分析[J]. 中华神经科杂
志, 2021, 54(4):362-367.
[31] Mojadidi MK, Gevorgyan R, Noureddin N, et al. The effect
of patent foramen ovale closure in patients with platypneaorthodeoxia
syndrome[J]. Catheter Cardiovasc Interv, 2015,
86(4):701-707.
[32] Pristipino C, Germonpré P, Toni D, et al. European position
paper on the management of patients with patent foramen
ovale. Part Ⅱ—Decompression sickness, migraine, arterial
deoxygenation syndromes and select high-risk clinical
conditions[J]. Eur Heart J, 2021, 42(16):1545-1553.
备注/Memo
- 备注/Memo:
-
基金项目：2021 年度河北省医学科学研究课题计划（20211276）
通信作者：宋秀娟， E-mail：songxiujuan1@126.com
常用功能
统计/Statistics
- 摘要浏览/Viewed1
- 全文下载/Downloads248
- 评论/Comments
